Observational study of buprenorphine treatment of opioid-dependent pregnant women in a family medicine residency: Reports on maternal and infant outcomes

Journal of the American Board of Family Medicine

Volumn 24, Issue 2, 2011, Pages 194-201

  O'Connor, Alane ^a   Alto, William ^a   Musgrave, Katje ^a   Gibbons, Daniel ^a   Llanto, Lalaine ^a   Holden, Selma ^a   Jonathan, Karnes ^a  

^a Maine Dartmouth Family Practice Residency   (United States)

Author keywords

Buprenorphine; Neonatal abstinence syndrome; Observational study; Opioids; Prenatal care

Indexed keywords

AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; COCAINE; METHADONE; NALOXONE; NEUROLEPTIC AGENT; PHENOBARBITAL;

ADULT; ARTICLE; BIRTH WEIGHT; BREAST FEEDING; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; FAMILY MEDICINE; FEMALE; HUMAN; INFANT WELFARE; MATERNAL SMOKING; MATERNAL WELFARE; NEWBORN; OBSERVATIONAL STUDY; OPIATE ADDICTION; OUTCOME ASSESSMENT; OUTPATIENT CARE; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; RESIDENT; RETROSPECTIVE STUDY; SCORING SYSTEM; WITHDRAWAL SYNDROME;

ADULT; BUPRENORPHINE; FAMILY PRACTICE; FEMALE; HUMANS; INFANT, NEWBORN; INTERNSHIP AND RESIDENCY; NARCOTIC ANTAGONISTS; NEONATAL ABSTINENCE SYNDROME; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952564737     PISSN: 15572625     EISSN: 15587118     Source Type: Journal    
DOI: 10.3122/jabfm.2011.02.100155     Document Type: Article

References (29)

1. Bolnick JM, Rayburn WF. Substance use disorders in women: special considerations during pregnancy. Obstet Gynecol Clin North Am 2003;30: 545-58. (Pubitemid 37420311)
2. US Centers for Disease Control and Prevention. Unintentional poisoning deaths-United States, 1999-2004. Available from: http://www.cdc.gov/mmwr/ preview/mmwrhtml/mm5605a1.htm. Accessed October 17, 2010.
3. Fischer G, Johnson RE, Eder H, et al. Treatment of opioid-dependent pregnant women with buprenorphine. Addiction 2000;95:239-44.
4. Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy. Obstet Gynecol Clin North Am 1998;25:139-51.
5. Barr GA, Jones K. Opiate withdrawal in the infant. Neurotoxicol Teratol 1994;16:219-25. (Pubitemid 24128575)
6. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009;(3):CD002209.
7. Center for Substance Abuse Treatment. Chapter 13. Medication-assisted treatment for opioid addiction during pregnancy. In: SAMHSA/CSAT treatment improvement protocols. Available from: http://www.ncbi.nlm.nih.gov/bookshelf/br. fcgi?book=hssamhsatip&part=A83488. Accessed October 17, 2010.
8. Jones HE, Martin PR, Heil SH, et al. Treatment of opioid-dependent pregnant women: clinical and research issues. J Subst Abuse Treat 2008;35:245-59.
9. Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005; 79:1-10. (Pubitemid 41557119)
10. Binder T, Vavrinkova B. Prospective, randomised, comparative study of the effect of buprenorphine, methadone, and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation, and course of the neonatal abstinence syndrome (NAS) in women followed up in the outpatient department. Neuro Endocrinol Lett 2008;29:80-6.
11. Johnson RE, Jones HE, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend 2003;70:S87-101.
12. Dunlop AJ, Panjari M, O'Sullivan H, et al. Clinical guidelines for the use of buprenorphine in pregnancy. Fitzroy, Turning Point Alcohol and Drug Centre; 2003.
13. Hamdan AH. Neonatal abstinence syndrome. Available from: http://emedicine.medscape.com/article/978763-overview. Accessed October 17, 2010.
14. Fischer G, Ortner R, Rohrmeister K, et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 2006;101:275-81.
15. Kayemba-Kay's S, Laclyde JP. Buprenorphine withdrawal syndrome in newborns: a report of 13 cases. Addiction 2003;98:1599-604.
16. Lacroix I, Berrebi A, Chaumerliac M, Lapeyre-Mestre M, Montastruc JL, Damase-Michel C. Buprenorphine in pregnant opioid-dependent women: first results of a prospective study. Addiction 2004; 99:209-14. (Pubitemid 38250755)
17. Kahila H, Saisto T, Kivitie-Kallio S, Haukkamaa M, Halmesmäki E. A prospective study on buprenorphine use in pregnancy: effects on maternal and neonatal outcome. Acta Obstet Gynecol Scand 2007; 86:185-90.
18. Lejeune C, Simmat-Durrand L, Gourarier L, Aubisson S, Groupe d'Etudes Grossesse et Addictions (GEGA). Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenorphine substitution. Drug Alcohol Depend 2006;82:250-7.
19. Jones HE, O'Grady K, Dahne J, et al. Management of acute postpartum pain in patients maintained on methadone and buprenorphine during pregnancy. Am J Drug Alcohol Abuse 2009;35:151-6.
20. Kakko J, Heilig M, Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend 2008;96:69-78.
21. Bakstad B, Sarfi M, Welle-Strand GK, Ravndal E. Opioid maintenance treatment during pregnancy: Occurrence and severity of neonatal abstinence syndrome. A national prospective study. Eur Addict Res 2009;15:128-34.
22. Kacinko SL, Jones HE, Johnson RE, Choo RE, Huestis MA. Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes. Clin Pharmacol Ther 2008;84:604-12.
23. Winklbaur B, Baewert A, Jagsch R, et al. Association between prenatal tobacco exposure and outcome of neonates born to opioid-maintained mothers. Eur Addict Res 2009;15:150-6.
24. Aagaard-Tillery KM, Porter TF, Lane RH, Varner MW, Lacoursiere DY. In utero tobacco exposure is associated with modified effects of maternal factors on fetal growth. Am J Obstet Gynecol 2008;198: 66.e1-6.
25. US Centers for Disease Control and Prevention. Tobacco use and pregnancy. Available from: http://www.cdc.gov/reproductivehealth/tobaccousepregnancy/ index.htm. Accessed October 17, 2010.
26. Johnson RE, Jones HE, Jasinski DR, et al. Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes. Drug Alcohol Depend 2001;63:97-103. (Pubitemid 32293533)
27. US Department of Health and Human Services. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. A treatment improvement protocol: TIP 40. Available from: http://buprenorphine.samhsa.gov/ Bup-Guidelines.pdf. Accessed October 17, 2010.
28. Lindemalm S, Nydert P, Svensson JO, Stahle L, Sarman I. Transfer of buprenorphine into breast milk and calculation of infant drug dose. J Hum Lact 2009;25:199-205.
29. Wachman EM, Byun J, Phillip BL. Breastfeeding rates among mothers of infants with neonatal abstinence syndrome. Breastfeed Med 2010;5:159-64.